Takeda Pharmaceutical Co.
and its partner Dainippon Sumitomo Pharma Company Limited
recently announced the approval of Dainippon's atypical
antipsychotic medication, Latuda, for the treatment of patients
with schizophrenia in Switzerland. It is the first approval of
Latuda in Europe. The Marketing Authorization Application was
submitted in Mar 2012.
According to the World Health Organization, schizophrenia
affects 24 million people globally. Roughly seven out of one
thousand adults (15-35 years of age) are affected by
We note that Dainippon and Takeda joined forces in Mar 2011,
for the joint development and exclusive commercialization of
Latuda by Takeda in the EU at that time excluding the UK,
Switzerland, Norway, Turkey and Russia.
Latuda has been discovered and developed by Dainippon. It
was approved in the U.S. for the treatment of schizophrenia in
Oct 2010 and for major depressive episodes associated with
bipolar I disorder in Jun 2013. It is marketed in the U.S. and
Canada by Sunovion Pharmaceuticals Inc., a wholly owned
subsidiary of Dainippon.
Latuda was accepted for review in the EU in Oct 2012 while in
Japan, phase III study for the treatment of schizophrenia is in
progress. It is also filed for approval with the Australian
authorities for the treatment of schizophrenia.
For the quarter ended Jul 31, 2013, Latuda generated sales of
$68 million, up 74% year over year, in the North American
Takeda carries a Zacks Rank #3 (Hold). Currently, companies
Questcor Pharmaceuticals Inc. (
), Biogen Idec Inc. (
Actelion Ltd. (
look well positioned in the pharma space with a Zacks Rank #1
ACTELION LTD (ALIOF): Get Free Report
BIOGEN IDEC INC (BIIB): Free Stock Analysis
QUESTCOR PHARMA (QCOR): Free Stock Analysis
TAKEDA PHARMACT (TKPYY): Get Free Report
To read this article on Zacks.com click here.